

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Neither this announcement nor any copy thereof may be released into or distributed, directly or indirectly, in the United States or any other jurisdiction where such release or distribution might be unlawful. This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase, or subscribe for any securities of the Company.

This announcement does not constitute or form a part of any offer to sell or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions where such offer is unlawful. The Company's shares mentioned in this announcement have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.



Beijing Biostar Pharmaceuticals Co., Ltd.

北京華昊中天生物醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2563)

COMPLETION OF SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

Reference is made to the announcements of Beijing Biostar Pharmaceuticals Co., Ltd. (the "**Company**") dated 7 May 2026 and 21 May 2026 (the "**Announcements**") in relation to, among others, the Subscription. Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcements.

The Board is pleased to announce that the conditions set out in the Subscription Agreement had been fulfilled and the Closing took place on 16 July, 2026 in accordance with the terms and conditions of the Subscription Agreement. The Company allotted and issued a total of 25,000,000 Subscription Shares to the Subscriber at the Subscription Price of HK\$4.00 per Subscription Share on the Closing Date.

The table below sets out the changes to the shareholding structure of the Company upon the Closing:

	Immediately before the Closing		Immediately after the Closing	
	Approximate percentage in the issued share capital of the Company (%) ⁽¹⁾		Approximate percentage in the issued share capital of the Company (%) ⁽¹⁾	
	Number of issued Shares		Number of issued Shares	
Shareholders				
Dr. Tang Li	40,505,885 ⁽²⁾			
	20,392,815 ⁽³⁾			
	19,220,863 ⁽⁴⁾			
	14,002,034 ⁽⁵⁾			
	5,000,724 ⁽⁶⁾			
	213,976 ⁽⁷⁾			
	<u>3,592,932⁽⁸⁾</u>			
	102,929,229 ⁽⁹⁾	28.23	102,929,229	26.42
Dr. Qiu Rongguo	205,585 ^(10 & 11)	0.06	205,585	0.05
Subscriber	4,170,800	1.14	29,170,800	7.49
Other Shareholders	<u>257,282,386</u>	<u>70.57</u>	<u>257,282,386</u>	<u>66.04</u>
Total number of Shares	<u>364,588,000</u>	<u>100</u>	<u>389,588,000</u>	<u>100</u>

Notes:

- (1) The aggregate of the percentage figures in the table above may not add up to the relevant sub-total or total percentage figures shown due to rounding of the percentage figures to two decimal places.
- (2) Baygen QT Inc. directly held 40,505,885 Shares (representing approximately 11.11% of the issued share capital). As Baygen QT Inc. is controlled by Dr. Tang, Dr. Tang is deemed to be interested in such Shares under the SFO.
- (3) Zhuhai Jingrong Haoyuan Investment Partnership (Limited Partnership) (珠海京蓉昊緣投資合夥企業(有限合夥)) directly held 20,392,815 Shares (representing approximately 5.59% of the issued share capital). As Zhuhai Jingrong Haoyuan Investment Partnership (Limited Partnership) is controlled by Dr. Tang, Dr. Tang is deemed to be interested in such Shares under the SFO.
- (4) Zhuhai Huajin Haoyuan Enterprise Management Partnership (Limited Partnership) (珠海華錦昊緣企業管理合夥企業(有限合夥)) directly held 19,220,863 Shares (representing approximately 5.27% of the issued share capital). As Zhuhai Huajin Haoyuan Enterprise Management Partnership (Limited Partnership) is controlled by Dr. Tang, Dr. Tang is deemed to be interested in such Shares under the SFO.

- (5) Zhuhai Huaxin Haoyuan Commercial Management Partnership (Limited Partnership) (珠海華欣昊緣商業管理合夥企業(有限合夥)) directly held 14,002,034 Shares (representing approximately 3.84% of the issued share capital). As Zhuhai Huaxin Haoyuan Commercial Management Partnership (Limited Partnership) is controlled by Dr. Tang, Dr. Tang is deemed to be interested in such Shares under the SFO.
- (6) Zhuhai Huarong Haoyuan Enterprise Management Partnership (Limited Partnership) (珠海華蓉昊緣企業管理合夥企業(有限合夥)) directly held 5,000,724 Shares (representing approximately 1.37% of the issued share capital). As Zhuhai Huarong Haoyuan Enterprise Management Partnership (Limited Partnership) is controlled by Dr. Tang, Dr. Tang is deemed to be interested in such Shares under the SFO.
- (7) Within the corporate interests held by Dr. Tang 213,976 Shares are directly held by Beijing Baygen Technologies Ltd. (北京北進緣科技有限公司). As Beijing Baygen is controlled by Dr. Tang, she is deemed to be interested in such Shares under the SFO.
- (8) Dr. Tang held 3,592,932 Shares as beneficial owner in her personal capacity.
- (9) Dr. Tang, the spouse of Dr. Qiu, held 102,929,229 Shares. By virtue of the SFO, Dr. Qiu is deemed to be interested in the Shares held by his spouse.
- (10) Within the corporate interests held by Dr. Qiu, 205,585 Shares are directly held by Beijing Baygen Technologies Ltd. (北京北進緣科技有限公司). As Beijing Baygen is controlled by Dr. Qiu, he is deemed to be interested in such Shares under the SFO.
- (11) Dr. Qiu, the spouse of Dr. Tang, held 205,585 Shares. By virtue of the SFO, Dr. Tang is deemed to be interested in the Shares held by her spouse.

By order of the Board
Beijing Biostar Pharmaceuticals Co., Ltd.
北京華昊中天生物醫藥股份有限公司
Dr. Tang Li
Chairman and Executive Director

Beijing, the PRC, 16 July 2026

As at the date of this announcement, the Board comprises (i) Dr. Tang Li, Dr. Qiu Rongguo, Mr. Zhang Cheng and Dr. Guan Jin as executive Directors; (ii) Mr. Tang Jin and Ms. Dai Xuefen as non-executive Directors; and (iii) Mr. Shiu Shu Ming, Dr. Ye Chengang and Dr. Zhu Xiaodong as independent non-executive Directors.